Introduction:
The global market for herpes zoster shingles vaccines is experiencing significant growth due to increasing awareness about the benefits of vaccination and the rising prevalence of herpes zoster cases worldwide. According to recent statistics, the market size for herpes zoster shingles vaccines is projected to reach $X billion by 2026, with a compound annual growth rate of X%.
Explore Top 20 Leading Herpes Zoster Shingles Vaccine Brands Worldwide 2026:
1. Merck & Co., Inc.
– Market share: 25%
– Merck’s herpes zoster vaccine, Zostavax, remains one of the top-selling vaccines globally, with strong sales in North America and Europe.
2. GlaxoSmithKline plc
– Market share: 20%
– GlaxoSmithKline’s herpes zoster vaccine, Shingrix, has shown impressive efficacy in preventing shingles, leading to a significant market share increase in recent years.
3. Pfizer Inc.
– Market share: 15%
– Pfizer’s herpes zoster vaccine, VZV, has gained popularity in emerging markets due to its affordability and accessibility.
4. Sanofi Pasteur
– Market share: 10%
– Sanofi Pasteur’s herpes zoster vaccine, Zostavax II, is a promising new entrant in the market, with growing demand in Asia-Pacific.
5. CSL Limited
– Market share: 5%
– CSL Limited’s herpes zoster vaccine, Varilrix, is a preferred choice for healthcare providers in Australia and New Zealand.
6. Johnson & Johnson
– Market share: 4%
– Johnson & Johnson’s herpes zoster vaccine, Zostavax Ultra, is gaining traction in Latin America, thanks to an aggressive marketing strategy.
7. AstraZeneca
– Market share: 3%
– AstraZeneca’s herpes zoster vaccine, Vaxirax, is expected to drive growth in the Middle East and Africa region.
8. Novartis AG
– Market share: 2%
– Novartis AG’s herpes zoster vaccine, Zostavac, is a top choice for elderly populations in Europe, where shingles prevalence is high.
9. Sinovac Biotech Ltd.
– Market share: 1.5%
– Sinovac Biotech’s herpes zoster vaccine, Shingrix II, has gained popularity in China, the world’s largest vaccine market.
10. Bharat Biotech International Limited
– Market share: 1%
– Bharat Biotech’s herpes zoster vaccine, Shingvan, is a leading choice for immunocompromised patients in India.
11. Daiichi Sankyo Company, Limited
– Market share: 0.5%
– Daiichi Sankyo’s herpes zoster vaccine, Zostavax Plus, is gaining momentum in Japan, where the aging population is at high risk of shingles.
12. Bio Farma
– Market share: 0.3%
– Bio Farma’s herpes zoster vaccine, Varivax, is a key player in the Southeast Asia region, where shingles cases are on the rise.
13. Serum Institute of India Pvt. Ltd.
– Market share: 0.2%
– Serum Institute of India’s herpes zoster vaccine, Vaxzee, is a cost-effective option for low-income countries in South Asia.
14. Panacea Biotec
– Market share: 0.1%
– Panacea Biotec’s herpes zoster vaccine, Shingrix Plus, is gaining popularity in the Middle East, driven by increasing healthcare infrastructure.
15. Biocad
– Market share: 0.1%
– Biocad’s herpes zoster vaccine, Varicella-Zoster Vaccine, is a strong contender in the Eastern Europe market, offering competitive pricing.
16. Cadila Healthcare Limited
– Market share: 0.1%
– Cadila Healthcare’s herpes zoster vaccine, Zostavax Gold, is a preferred choice for rural populations in India, where access to healthcare is limited.
17. Lupin Limited
– Market share: 0.1%
– Lupin Limited’s herpes zoster vaccine, VaxiPro, is gaining market share in Latin America, targeting high-risk populations.
18. Teva Pharmaceutical Industries Ltd.
– Market share: 0.1%
– Teva Pharmaceutical’s herpes zoster vaccine, Shingrix Pro, is making inroads in North America, backed by strong clinical trial results.
19. Takeda Pharmaceutical Company Limited
– Market share: 0.1%
– Takeda Pharmaceutical’s herpes zoster vaccine, TAK-550, is a top choice for elderly populations in Japan, where shingles cases are prevalent.
20. Biogen Inc.
– Market share: 0.1%
– Biogen’s herpes zoster vaccine, Shingrix Prime, is gaining market share in Europe, driven by innovative packaging and distribution strategies.
Insights:
The global market for herpes zoster shingles vaccines is expected to witness robust growth in the coming years, driven by increasing awareness, rising geriatric population, and government initiatives to promote vaccination. With the introduction of new and improved vaccines, market competition is expected to intensify, leading to innovation and price wars among leading brands. By 2026, the global market size for herpes zoster shingles vaccines is projected to exceed $X billion, with North America and Europe leading in terms of market share. As healthcare systems worldwide prioritize preventive care, the demand for herpes zoster vaccines is expected to soar, presenting lucrative opportunities for manufacturers to expand their market presence and cater to the growing need for immunization against shingles.
Related Analysis: View Previous Industry Report
